Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Developing countries could exploit traditional medicine to kick-start biotech, but only if their products measure up to the demands of Western regulators. Paroma Basu reports.
The successful immortalization of neural progenitor cells via the overexpression of telomerase prompts several questions for those intending to develop somatic stem cell therapies for neurological disease.
Before they fell into disfavor, legally independent affiliates of biotech companies—special purpose entities—had supported the development of several blockbuster drugs. Are they about to stage a comeback?